-
Leveraging Large-Language Models for Medical Code List Creation: An Example Using the Charlson Comorbidity Index
Sep 9, 2025, 16:22 PM -
Costing Analysis for the Management of Localized Renal Cell Carcinoma From the UK NHS Perspective
Sep 9, 2025, 16:22 PM -
Examining the Opportunity Costs Due to Diabetic Macular Edema Taking Into Account Access Barriers Evaluated in the Barometer Program Survey in Colombia
Sep 9, 2025, 16:22 PM -
Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis
Sep 9, 2025, 16:22 PM -
The Micro-Meso-Macro (3M) Impact Framework: Capturing Health System Value Across Interacting Levels
Sep 9, 2025, 16:22 PM -
Unmet Needs in NICE HTAs: Insights From Obesity and Diabetes Submissions
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study
Sep 9, 2025, 16:22 PM -
Preventing Bleeds in Pediatric Patients With Hemophilia A: Which Factor Replacement Therapy Offers the Best Protection and at What Cost?
Sep 9, 2025, 16:22 PM -
Value-Based Decision Making in a Social Security Provider in Argentina for Oncology and Oncohematology Drugs
Sep 9, 2025, 16:22 PM -
Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025
Sep 9, 2025, 16:22 PM -
Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States
Sep 9, 2025, 16:22 PM -
From Code to Quality: Identifying Quality Assurance Steps for AI Integration in Qualitative Healthcare Research: A Comparative Study of ChatGPT, Atlas.ti, and Traditional Coding
Sep 9, 2025, 16:22 PM -
Healthcare and Economic Burden of Intravenous and Subcutaneous Immunoglobulin Treatment in Three Autoimmune Neuromuscular Diseases: A Bicentric Spanish Experience
Sep 9, 2025, 16:22 PM -
CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?
Sep 9, 2025, 16:22 PM -
Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing Source Exploration...
Sep 9, 2025, 16:22 PM -
Launch Price Dynamics of Targeted Therapies in NSCLC: Dissecting the Cost and Value Across Biomarker Segments
Sep 9, 2025, 16:22 PM -
Knowledge and Practices Regarding Expired Medications Among Saudi Citizens
Sep 9, 2025, 16:22 PM -
Occurrence of Exacerbations and Mortality in High-Risk Chronic Obstructive Pulmonary Disease Patients While on Treatment With Dual or Triple Inhaled Therapy: Results From the SIRIUS Observational Study in the US
Sep 9, 2025, 16:22 PM -
HTA Requirements for Medical Technologies in Germany
Sep 9, 2025, 16:22 PM -
Optimizing PICO Scoping in EU HTA: Lessons From a HTA Coordination Group PICO Exercise in Advanced NSCLC to Inform Future Best Practice
Sep 9, 2025, 16:22 PM
